Should Drug Companies Stop Pursuing Amyloid In Treatments For Alzheimer’s?

The pharmaceutical industry has been on a 30 year mission to develop a drug to treat Alzheimer’s disease. The culprits behind the disease, they thought, were the amyloid plaques that build up in the brains of these patients. For many decades removing these plaques to treat Alzheimer’s was the goal.

But then drug after drug targeting amyloid failed to improve the symptoms of Alzheimer’s—the so-called “amyloid hypothesis” wasn’t bearing out. But drug companies kept developing and testing drugs that attacked amyloid from every angle—perhaps at the expense of pursuing other avenues of treatment.

Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature

Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Herein, a total of nine consecutive patients with brain tumours are described as case series; all patients received CBD in a daily dose of 400 mg concomitantly to the standard therapeutic procedure of maximal resection followed by radiochemotherapy.

Antipsychotic Drugs Linked to More Hospitalizations Among Dementia Patients

Antipsychotic drugs are most commonly used to treat mental health conditions like schizophrenia or bipolar disorder, but they’re also often prescribed to patients with Alzheimer’s or dementia to alleviate some of the most difficult symptoms.

However, this may come with some negative side effects: A new study finds that people with dementia who were using antipsychotic drugs were more likely to spend time in the hospital than those who weren’t on antipsychotics.

Get one-month FREE access to our online yoga membership site.

Sign up to our mailing list to get one month free (Value $97)

We guard your privacy and will not sell/share your personal information.
We will contact you with information related of things of interest on an occasional basis.
To read our Privacy Policy Click here